Evidence consistency analysis of the effect of a low-FODMAP diet on the abundance of Bifidobacterium and Faecalibacterium prausnitzii in patients with irritable bowel syndrome
- 1School of Public Health, Wuhan University of Science and Technology
- 2Medical Imaging Department, Wuhan University of Science and Technology Hospital
- 3Institute of Food Safety and Nutrition Hygiene, Wuhan Center for Disease Control and Prevention
Abstract
Background: The low-FODMAP diet is recommended by clinical guidelines as an effective dietary strategy for alleviating symptoms in patients with irritable bowel syndrome (IBS). However, its effect on Bifidobacterium and Faecalibacterium prausnitzii ( F. prausnitzii ) remains unclear, largely due to methodological heterogeneity.
Methods: We systematically searched the literature up to September 2026 for randomized controlled trials comparing low-FODMAP diets with control diets in adults with IBS. Given the high methodological heterogeneity across studies, we performed a direction-of-effect and consistency analysis (vote counting and sign test) instead of a traditional meta-analysis.
Results: 12 RCTs were included. For Bifidobacterium (11 studies), 9 (81.8%) reported a decrease and 2 reported no change; the sign test confirmed a consistent reduction ( p = 0.033). A sensitivity analysis including only studies with direct between-group comparisons (9 studies) was consistent with the aforementioned analysis (8 reported a decrease, p = 0.020). For F. prausnitzii (7 studies), the evidence was inconsistent: 2 reported a decrease, 4 reported no change, and 1 reported an increase, with no statistically significant trend.
Conclusion: Most current evidence indicates that a low FODMAP diet reduces the abundance of Bifidobacterium in IBS patients, while its effect on F. prausnitzii remains unclear. This finding enables clinicians to conduct more evidence-based counseling with patients, clarifying the specific effects (and non-effects) of the low-FODMAP diet on microbiota and facilitating informed decision-making regarding dietary management. Furthermore, future research should investigate the dynamics of microbiota during the reintroduction phase and consider patient microbiota subtypes to clarify the overall impact of the diet on the microbiota.
Systematic review registration: This systematic review has been registered with PROSPERO (International Prospective Register of Systematic Reviews) under the registration number CRD420261351146. The publicly accessible URL is: https://www.crd.york.ac.uk/PROSPERO/ .
Related
- Identification and characterization of novel Faecalibacterium prausnitzii strains from infant gut microbiota with potential pharmabiotic applications
- Potential mechanisms of Bifidobacterium-mediated synergistic antibiotic eradication of drug-resistant Helicobacter pylori
- Beneficial effects of a Multistrain Bifidobacterium probiotic on gut health and immunity of indonesian children
- Preventive administration of Bifidobacterium animalis subsp. lactis HEM20–01 attenuates the development of atopic dermatitis-like inflammation in mice, along with gut microbial and succinate alterations
- Therapeutic potential of Sishen Pill: modulating intestinal mucosal microbiota and barrier function in diarrhea-predominant irritable bowel syndrome with Spleen-Kidney Yang Deficiency
BibTeX
@article{cao2026evidence,
title = {{Evidence consistency analysis of the effect of a low-FODMAP diet on the abundance of Bifidobacterium and Faecalibacterium prausnitzii in patients with irritable bowel syndrome}},
author = {Bingqian Cao and Li Zhou and Shouzhang Hu and Yue Huang},
journal = {Frontiers in Microbiology},
year = {2026},
month = oct,
doi = {10.3389/fmicb.2026.1948754},
url = {https://www.frontiersin.org/articles/10.3389/fmicb.2026.1948754/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Evidence consistency analysis of the effect of a low-FODMAP diet on the abundance of Bifidobacterium and Faecalibacterium prausnitzii in patients with irritable bowel syndrome
AU - Bingqian Cao
AU - Li Zhou
AU - Shouzhang Hu
AU - Yue Huang
PY - 2026
DA - 2026/10/06
JO - Frontiers in Microbiology
DO - 10.3389/fmicb.2026.1948754
UR - https://www.frontiersin.org/articles/10.3389/fmicb.2026.1948754/full
AB - Background: The low-FODMAP diet is recommended by clinical guidelines as an effective dietary strategy for alleviating symptoms in patients with irritable bowel syndrome (IBS). However, its effect on Bifidobacterium and Faecalibacterium prausnitzii ( F. prausnitzii ) remains unclear, largely due to methodological heterogeneity. Methods: We systematically searched the literature up to September 2026 for randomized controlled trials comparing low-FODMAP diets with control diets in adults with IBS. Given the high methodological heterogeneity across studies, we performed a direction-of-effect and consistency analysis (vote counting and sign test) instead of a traditional meta-analysis. Results: 12 RCTs were included. For Bifidobacterium (11 studies), 9 (81.8%) reported a decrease and 2 reported no change; the sign test confirmed a consistent reduction ( p = 0.033). A sensitivity analysis including only studies with direct between-group comparisons (9 studies) was consistent with the aforementioned analysis (8 reported a decrease, p = 0.020). For F. prausnitzii (7 studies), the evidence was inconsistent: 2 reported a decrease, 4 reported no change, and 1 reported an increase, with no statistically significant trend. Conclusion: Most current evidence indicates that a low FODMAP diet reduces the abundance of Bifidobacterium in IBS patients, while its effect on F. prausnitzii remains unclear. This finding enables clinicians to conduct more evidence-based counseling with patients, clarifying the specific effects (and non-effects) of the low-FODMAP diet on microbiota and facilitating informed decision-making regarding dietary management. Furthermore, future research should investigate the dynamics of microbiota during the reintroduction phase and consider patient microbiota subtypes to clarify the overall impact of the diet on the microbiota. Systematic review registration: This systematic review has been registered with PROSPERO (International Prospective Register of Systematic Reviews) under the registration number CRD420261351146. The publicly accessible URL is: https://www.crd.york.ac.uk/PROSPERO/ .
SN - 1664-302X
ER -